Acute cannabidiol administration reduces alcohol craving and cue-induced nucleus accumbens activation in individuals with alcohol use disorder: the double-blind randomized controlled ICONIC trial.

Dose-dependent effects of oral cannabidiol and delta-9-tetrahydrocannabinol on serum anandamide and related N-acylethanolamines in healthy volunteers.

Alterations to sphingolipid metabolism from antipsychotic administration in healthy volunteers are restored following the use of cannabidiol

Cannabidiol and its Potential Evidence-Based Psychiatric Benefits.

ReTimeML: a retention time predictor that supports the LC-MS/MS analysis of sphingolipids.

Simultaneous Assessment of Serum Levels and Pharmacologic Effects of Cannabinoids on Endocannabinoids and N-Acylethanolamines by Liquid Chromatography-Tandem Mass Spectrometry.

Fatty acid amide hydrolase inhibition alleviates anxiety-like symptoms in a rat model used to study post-traumatic stress disorder.

Cannabidiol enhances cerebral glucose utilization and ameliorates psychopathology and cognition: A case report in a clinically high-risk mental state.

Chronic Psychosocial Stress Causes Increased Anxiety-Like Behavior and Alters Endocannabinoid Levels in the Brain of C57Bl/6J Mice.

Cannabis use and psychosis: a review of reviews.

Cannabinoids and the endocannabinoid system in anxiety, depression, and dysregulation of emotion in humans.

Das ZI-Track-Konzept in der Behandlung psychotischer Störungen [The CIMH track concept in the treatment of psychotic disorders].

Multimodal Psychotherapeutic Inpatient Therapy of Depression Is Successful in Patients With High Cytokine Production.

Youth Mental Health Tracker: protocol to establish a longitudinal cohort and research database for young people attending Australian mental health services.

Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Attention: A Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers.

Multimodel inference for biomarker development: an application to schizophrenia.

Familial abnormalities of endocannabinoid signaling in schizophrenia.

Right care, first time: a highly personalised and measurement-based care model to manage youth mental health.

Neural correlates of binocular depth inversion illusion in antipsychotic-naïve first-episode schizophrenia patients.

Different pharmaceutical preparations of Δ9 -tetrahydrocannabinol differentially affect its behavioral effects in rats.

Resting-state gamma-band power alterations in schizophrenia reveal E/I-balance abnormalities across illness-stages.

Probing the endocannabinoid system in healthy volunteers: Cannabidiol alters fronto-striatal resting-state connectivity.

Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention.

Cannabidiol zur Verbesserung der Genesung in frühen Stadien einer Schizophrenie.

Evidence of microglial activation following exposure to serum from first-onset drug-naïve schizophrenia patients.

Virus discovery analyses on post-mortem brain tissue and cerebrospinal fluid of schizophrenia patients.

Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of patients with major depression: a preliminary prospective study.

Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.

Putative Role of Endocannabinoids in Schizophrenia.

Motor impairment and compensation in a hemiparkinsonian rat model: correlation between dopamine depletion severity, cerebral metabolism and gait patterns.

Evidence of microglial activation following exposure to serum from first-onset drug-naïve schizophrenia patients.

Pathogen-mediated NMDA receptor autoimmunity and cellular barrier dysfunction in schizophrenia.

Reduced superoxide dismutase-1 (SOD1) in cerebrospinal fluid of patients with early psychosis in association with clinical features.

Association of anandamide with altered binocular depth inversion illusion in schizophrenia.

Schizophrenia-risk and urban birth are associated with proteomic changes in neonatal dried blood spots.

Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients.

Differential melatonin alterations in cerebrospinal fluid and serum of patients with major depressive disorder and bipolar disorder.

Candida albicans exposures, sex specificity and cognitive deficits in schizophrenia and bipolar disorder.

Therapeutic Potential of Cannabinoids in Psychosis.

What is the promise of nicotinergic compounds in schizophrenia treatment?

Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence.

The Functional Networks of Prepulse Inhibition: Neuronal Connectivity Analysis Based on FDG-PET in Awake and Unrestrained Rats.

Towards a blood-based diagnostic panel for bipolar disorder.

The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics.

Cannabinoids and schizophrenia.

Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset.

Enhanced Functional Activity of the Cannabinoid Type-1 Receptor Mediates Adolescent Behavior.

Serum proteomic profiling of major depressive disorder.

IgG dynamics of dietary antigens point to cerebrospinal fluid barrier or flow dysfunction in first-episode schizophrenia.

Melatonin in humans physiological and clinical studies. Journal of neural transmission.

Inflammatory molecular signature associated with infectious agents in psychosis.

Hypocretin in cerebrospinal fluid is positively correlated with Tau and pTau.

Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways.

Increased CB2 mRNA and anandamide in human blood after cessation of cannabis abuse.

Oleoylethanolamide and human neural responses to food stimuli in obesity.

Source-reconstruction of event-related fields reveals hyperfunction and hypofunction of cortical circuits in antipsychotic-naive, first-episode schizophrenia patients during Mooney face processing.

Neural correlates of sensorimotor gating: a metabolic positron emission tomography study in awake rats.

Fatty acid ethanolamide levels are altered in borderline personality and complex posttraumatic stress disorders.

Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations.

Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia.

Distinct molecular phenotypes in male and female schizophrenia patients.

Marked reduction of soluble superoxide dismutase-1 (SOD1) in cerebrospinal fluid of patients with recent-onset schizophrenia.

Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms.

Application of meta-analysis methods for identifying proteomic expression level differences.

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.

Differential phosphorylation of serum proteins reflecting inflammatory changes in schizophrenia patients.

Gastrointestinal inflammation and associated immune activation in schizophrenia.

Identification of a biological signature for schizophrenia in serum.

Anandamide dysfunction in prodromal and established psychosis.

Medical needs in the treatment of psychotic disorders.

Molecular sex differences in human serum.

Protein phosphorylation patterns in serum from schizophrenia patients and healthy controls.

Differential effects on T-cell function following exposure to serum from schizophrenia smokers.

Global proteomic profiling reveals altered proteomic signature in schizophrenia serum.

Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naïve schizophrenia patients.

Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia.

Identification of N-glycosylation changes in the CSF and serum in patients with schizophrenia.

The neurobiology of schizophrenia: new leads and avenues for treatment.

Alterations of primary fatty acid amides in serum of patients with severe mental illness.

Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia.

Cannabinoid exposure in pubertal rats increases spontaneous ethanol consumption and NMDA receptor associated protein levels.

Characterization of the human serum depletome by label-free shotgun proteomics.

Chronic pubertal cannabinoid treatment as a behavioural model for aspects of schizophrenia: effects of the atypical antipsychotic quetiapine.

Impaired glycolytic response in peripheral blood mononuclear cells of first-onset antipsychotic-naive schizophrenia patients.

Cerebrospinal fluid diagnostics in first-episode schizophrenia.

Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis.

Binocular depth inversion as a paradigm of reduced visual information processing in prodromal state, antipsychotic-naïve and treated schizophrenia.

Clinical bioinformatics for complex disorders: a schizophrenia case study.

Sleep deprivation increases oleoylethanolamide in human cerebrospinal fluid.

The endocannabinoid system as a target for modelling psychosis.

Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis.

Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial.

Cannabis and psychiatric disorders: it is not only addiction.

Combining Molecular and Physiological Data of Complex Disorders.

High-frequency gamma-band oscillations during perceptual organisation in chronic and first-episode schizophrenia patients.

Improvement of general symptoms in a chronic psychotic patient treated with finasteride: case report.

Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues.

Does anandamide elevation in cerebrospinal fluid protect against transition into frank psychosis?

Acute and chronic cannabinoid treatment differentially affects recognition memory and social behavior in pubertal and adult rats.

High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides.

2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia.

Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis.

Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use.

Cessation of complex visual hallucinations during treatment with mirtazapine.

CSF biomarker discovery using label-free nano-LC-MS based proteomic profiling: technical aspects.

Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use.

Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry.

Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression.

Gabapentin's acute effect on mood profile -- a controlled study on patients with alcohol withdrawal.

Label-free LC-MS/MS quantitative proteomics for large-scale biomarker discovery in complex samples.

Peptide correlation: a means to identify high quality quantitative information in large-scale proteomic studies.

Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry.

The initial prodrome of schizophrenia: different duration, different underlying deficits?

Wirksamkeit und Verträglichkeit von Quetiapin in der stationären Akutbehandlung schizophrener Psychosen: Eine Anwendungsbeobachtung [Efficacy and tolerability of quetiapine in hospitalised schizophrenic patients during the acute treatment phase: a PMS study].

Clozapine alone versus clozapine and risperidone for refractory schizophrenia.

Cytomegalovirus and schizophrenia.

Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis.

Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness.

Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia.

Studienlage zur Behandlung der Cannabisabhängigkeit [A survey on trials focussing on the treatment of cannabis-dependence].

Systems-theory of psychosis--the relevance of "internal censorship".

The endocannabinoid anandamide in CSF is related to the patterns of cannabis use in first-episode schizophrenia.

Antibodies to infectious agents in individuals with recent onset schizophrenia.

AWMF-Leitlinie: Cannabis-bezogene Störungen [AWMF-guideline: disorders related to cannabis].

Cannabis-associated psychosis: current status of research.

Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms.

Endogenous cannabinoids and their neurobiological and functional role in schizophrenia spectrum disorders.

Oxcarbazepine as an adjunct for schizophrenia.

Evidence for a role of endogenous cannabinoids in schizophrenia.

The natural cannabinoid cannabidiol in the treatment of schizophrenia.

Evidence for a role of endogenous cannabinoids in schizophrenia.

Treatment of acute alcohol withdrawal with gabapentin: results from a controlled two-center trial.

Comorbid anxiety and affective disorder in alcohol-dependent patients seeking treatment. the first Multicentre Study in Germany.

Different effects of nabilone and cannabidiol on binocular depth inversion in Man.

Carbamazepine as an adjunct in the treatment of schizophrenia-like psychosis related to cannabis abuse.

Effects of synthetic delta9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man.

Elevated endogenous cannabinoids in schizophrenia.

Manic episode due to gabapentin treatment.

Nichtlineare Dynamik und das „Unerwartete“ in der Psychiatrie.

Treatment of alcohol withdrawal syndrome with gabapentin.

Cannabinoid/anandamide system and schizophrenia: is there evidence for association?

The effects of tetrahydrocannabinol on the recognition of emotionally charged words: an analysis using event-related brain potentials.

Propsychotische Veränderung der binokulären Tiefeninversion durch Schlafentzug [Pro-psychotic change of binocular depth inversion by sleep deprivation].

Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system.

Impaired binocular depth inversion in patients with alcohol withdrawal.

Oxcarbazepine, Carbamazepine and Valproate in the Treatment of Affective and Disintegrative Psychiatric Disorders.

Visual 3D illusion: a systems-theoretical approach to psychosis.

Effects of pentetrazol on neuronal activity and on extracellular calcium concentration in rat hippocampal slices.